Pfizer Inc (PFE) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 27 2026 to Sep 28 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Pfizer Inc  (NYSE: PFE)

Pfizer Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Pfizer Inc in the third quarter 2026?
Pfizer Inc achieved a return on average equity (ROE) of 4.62 % in its third quarter 2026, which is below Pfizer Inc's average return on equity, which stands at 16.85%.

ROE fell compared to the second quarter 2026, despite the net income growth of % from the second quarter 2026.

Within the Major Pharmaceutical Preparations industry 55 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1642, from total ROE ranking in the second quarter 2026 at 1833.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 27 2026)
III. Quarter		 (Jun 28 2026)
II. Quarter		 (Mar 29 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 28 2025)
III. Quarter
Y / Y Equity Change -4.08 % -3.95 % -0.26 % -1.95 % -
Y / Y Net Income Change -8.68 % - -9.32 % - -20.63 %
Net Income (TTM) in Millions 4,062 4,370 7,535 7,812 9,869
Return On Equity (TTM) 4.62 % 4.91 % 8.39 % 8.69 % 10.93 %
PFE's Total Ranking # 1642 # 1833 # 1290 # 1132 # 1544
Equity (TTM) in Millions 89,301 85,492 90,404 86,775 93,096
Seq. Equity Change 4.46 % -5.43 % 4.18 % -6.79 % 4.59 %
Seq. Net Income Change - - - - 21.24 %

Back to PFE Management Effectiveness >> PFE's 5 Years Annual ROE >> Compare PFE ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 56
Sector # 167
Overall # 1642

Return On Equity Statistics
High Average Low
38.13 %
16.85 %
-2.8 %
(Apr 01 2018)  



  News about Pfizer Inc Return on Equity ROE

Pfizer Showcases Innovations in Infectious Disease Research at IDWeek 2025 Amid Financial Pressures,

Pfizer Inc. (NYSE: PFE) is set to showcase its latest advancements in the realm of respiratory health and infectious disease research at the upcoming IDWeek 2025 congress, taking place from October 19-22, 2025, in Atlanta, Georgia. The company is gearing up to present data derived from a total of 46 abstracts that encompass both company-led studies and collaborations with various partners. These presentations will illuminate significant strides made in the prevention and treatment of infectious diseases, underscoring Pfizer’s ongoing commitment to innovation in healthcare.IDWeek is an annual event that brings together a wide array of healthcare professionals, researchers, and industry leaders from around the globe to exchange knowledge and insights on infectious diseases, including COVID-19, HIV, and other respiratory conditions. For Pfizer, IDWeek 2025 presents a vital platform to demonstrate its cutting-edge scientific progress and to foster collaborations with global health experts.



PFE Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 86,775 88,497 89,288 95,916 77,462
Y / Y Equity Change -1.95 % -0.89 % -6.91 % 23.82 % 22.04 %
Net Income in Millions 7,812 8,062 2,158 31,407 22,025
Y / Y Net Income Change -3.1 % 273.59 % -93.13 % 42.6 % 128.19 %
Return On Equity 9 % 9.11 % 2.42 % 32.74 % 28.43 %

Back to PFE Management Effectiveness >> PFE's 5 Years Annual ROE >> Compare PFE ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 9 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PFE's' Return on Equity at Yahoo Finance
PFE's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PFE's Competitors
Subscribers only: Roe for Pfizer Inc's Suppliers
Subscribers only: Return On Equity for PFE's Customers




Companies with similar Return On Equity at Sep 27 2026, within Healthcare Sector ROE
Inspire Medical Systems inc   12.49 %
Haemonetics Corporation  12.07 %
Labcorp Holdings Inc   11.55 %
Henry Schein Inc   11.29 %
Medinotec Inc   10.97 %
Tactile Systems Technology Inc   10.73 %
Penumbra Inc  10.44 %
Teleflex Incorporated  9.67 %
Merit Medical Systems Inc  9.65 %
U S Physical Therapy Inc  9.48 %
Pacific Health Care Organization Inc  8.10 %
Incyte Corporation  7.08 %
Conmed Corporation  7.07 %
Teva Pharmaceutical Industries Limited  6.37 %
Integer Holdings Corporation  6.02 %
Avantor Inc   5.96 %
Ligand Pharmaceuticals Incorporated  5.22 %
Lifestance Health Group Inc   4.82 %
Jazz Pharmaceuticals Plc  4.62 %
Pfizer Inc  4.62 %
Innovage Holding Corp   4.52 %
Icu Medical Inc  2.81 %
Biogen Inc   1.86 %
Integra Lifesciences Holdings Corp  1.24 %

Date modified: 2026-11-04T15:23:31+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.